Add another name to the list: In mid-November the beleaguered biotech outfit ImClone Systems Inc. announced the resignation of John Landes, the company’s senior vice president for legal affairs.
Resignation marked the end of a long, difficult stretch for Landes. Early last year-months before the allegations of insider trading against the company became public–Landes was demoted from general counsel to senior vice president. Then, in July, congressional investigators added Landes’s name to the roster of insiders alleged to have sold ImClone stock days before the company announced the Food and Drug Administration’s rejection of its application to market a cancer drug. Finally, last October, the House Energy and Commerce Committee ridiculed Landes and other ImClone directors and officers for not sniffing out wrongdoing at ImClone earlier.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
